Eye Drops for Wet Age-Related Macular Degeneration
Part of Eyes & vision clinical trials.
This study tests whether a new eye drop medication (SCAI-005) can help people with wet age-related macular degeneration (a serious eye condition affecting central vision in older adults) who have already responded well to regular eye injections. The goal is to see if eye drops might work as an alternative treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You were diagnosed with wet macular degeneration in your study eye within the last 3 years
- You have had at least 3 anti-VEGF eye injections for this condition, with the last one more than 12 weeks ago
- You have active abnormal blood vessel growth (MNV) in your eye with fluid visible on imaging
- Your eye thickness measurement is 450 micrometers or less
- Your vision in the study eye is between 20/25 and 20/320 (moderate to significant vision loss)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests an investigational eye injection called AL-001 for people with wet age-related macular degeneration (AMD) that has responded to previous anti-VEGF treatment. The goal is to see if it improves vision and is safe.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.